An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOCIEDAD ESPANOLA DE PSIQUIATRIA BIOLOGICA (SEPB)
Autores
LEON, J. de
SCHORETSANITIS, G.
SMITH, R. L.
MOLDEN, E.
SOLISMAA, A.
SEPPäLä, N.
KOPEčEK, M.
ŠVANCER, P.
OLMOS, I.
RICCIARDI, C.
Citação
PSIQUIATRIA BIOLOGICA, v.30, n.3, article ID 100415, p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This is the Spanish translation of an international guideline which proposes improving clozapine package inserts worldwide by using ancestry-based: 1) dosing and 2) titration. Adverse drug reaction (ADR) databases suggest clozapine: 1) is the third most toxic drug in the United States (US), and 2) produces worldwide pneumonia mortality four times greater than that of agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers require the lowest dose and male smokers the highest dose). Poor metabolizer (PM) status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity or inflammation with C-reactive protein (CRP) elevations. People with ancestry from Asia (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/ml. Daily doses of 300-600 mg/day are recommended in the US. Slow personalized titration may prevent early ADRs (including syncope, myocarditis and pneumonia). The core of this guideline consists of six personalized titration schedules for inpatients: 1) Asian/Amerindian ancestry with lower metabolism (in cases of obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) Asian/Amerindian ancestry with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (in cases of obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US of non-Asian/Amerindian ancestry with lower clozapine metabolism (in cases of obesity or valproate) needing 150-300 mg/day, and 6) in the US of non-Asian/Amerindian ancestry with average clozapine metabolism needing 300-600 mg/day. Baseline and weekly CRP monitoring for at least 4 weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Palavras-chave
Asian continental ancestry group, Clozapine/adverse effects, Clozapine/blood, Clozapine/metabolism, Clozapine/therapeutic use, Clozapine/toxicity, CYP1A2, Drug labeling, European continental ancestry group, Infection, Inflammation, Mortality/drug effects, Native American continental ancestry group, Sex, Smoking
URI
https://observatorio.fm.usp.br/handle/OPI/58638
Referências
  1. de Leon J., Schoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppala N., Et al., An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels, Pharmacopsychiatry., 55, 2, pp. 73-86, (2022)
  2. de Leon J., Ruan C.J., Schoretsanitis G., De Las C.C., A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology, Psychother Psychosom, 89, 4, pp. 200-204, (2020)
  3. Kane J., Honigfeld G., Singer J., Meltzer H., Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine, Arch Gen Psychiatry, 45, 9, pp. 789-796, (1988)
  4. de Leon J., Ruan C.J., Schoretsanitis G., Kane J.M., Dose and safety concerns of clozapine: worldwide package inserts need revisions, Schizophr Res, 216, pp. 2-4, (2020)
  5. Nielsen J., Young C., Ifteni P., Kishimoto T., Xiang Y.T., Schulte P.F., Et al., Worldwide differences in regulations of clozapine use, CNS Drugs, 30, 2, pp. 149-161, (2016)
  6. Howes O.D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N.J., Birnbaum M.L., Et al., Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on diagnosis and terminology, Am J Psychiatry, 174, 3, pp. 216-229, (2017)
  7. Siskind D., McCartney L., Goldschlager R., Kisely S., Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis, Br J Psychiatry, 209, 5, pp. 385-392, (2016)
  8. Samara M.T., Dold M., Gianatsi M., Nikolakopoulou A., Helfer B., Salanti G., Et al., Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis, JAMA Psychiatry, 73, 3, pp. 199-210, (2016)
  9. Huhn M., Nikolakopoulou A., Schneider-Thoma J., Krause M., Samara M., Peter N., Et al., Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis, Lancet., 394, 10202, pp. 939-951, (2019)
  10. Land R., Siskind D., McArdle P., Kisely S., Winckel K., Hollingworth S.A., The impact of clozapine on hospital use: a systematic review and meta-analysis, Acta Psychiatr Scand, 135, 4, pp. 296-309, (2017)
  11. Masuda T., Misawa F., Takase M., Kane J.M., Correll C.U., Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies, JAMA Psychiatry, 76, 10, pp. 1052-1062, (2019)
  12. Rohde C., Polcwiartek C., Kragholm K., Ebdrup B.H., Siskind D., Nielsen J., Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study, Acta Psychiatr Scand, 137, 1, pp. 47-53, (2018)
  13. Chopra N., Ruan C.J., McCollum B., Et al., High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers, Rev Colomb Psiquiatr, 49, pp. 84-95, (2020)
  14. Subramanian S., Vollm B.A., Huband N., Clozapine dose for schizophrenia, Cochrane Database Syst Rev, 6, 6, (2017)
  15. Zhou Y., Ingelman-Sundberg M., Lauschke V.M., Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects, Clin Pharmacol Ther, 102, 4, pp. 688-700, (2017)
  16. Allorge D., Chevalier D., Lo-Guidice J.M., Cauffiez C., Suard F., Baumann P., Et al., Identification of a novel splice-site mutation in the CYP1A2 gene, Br J Clin Pharmacol, 56, 3, pp. 341-344, (2003)
  17. Ito M., Katono Y., Oda A., Hirasawa N., Hiratsuka M., Functional characterization of 20 allelic variants of CYP1A2, Drug Metab Pharmacokinet, 30, 3, pp. 247-252, (2015)
  18. Soyama A., Saito Y., Hanioka N., Maekawa K., Komamura K., Kamakura S., Et al., Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population, Drug Metab Pharmacokinet, 20, 2, pp. 24-33, (2005)
  19. Bender S., Eap C.B., Very high cytochrome P4501A2 activity and nonresponse to clozapine, Arch Gen Psychiatry, 55, 1, pp. 1048-1050, (1998)
  20. VanderZwaag C., McGee M., McEvoy J.P., Freudenreich O., Wilson W.H., Cooper T.B., Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges, Am J Psychiatry, 153, 12, pp. 1579-1584, (1996)
  21. Cho J., Hayes R.D., Jewell A., Kadra G., Shetty H., MacCabe J.H., Et al., Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study, Acta Psychiatr Scand, 139, 3, pp. 237-247, (2019)
  22. Winckel K., Siskind D., Hollingworth S., Wheeler A., Clozapine-induced myocarditis: separating the wheat from the chaff, Aust N Z J Psychiatry, 49, 2, (2015)
  23. Schulte P., What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia, Clin Pharmacokinet, 42, 7, pp. 607-618, (2003)
  24. de Leon J., Ruan C.J., Schoretsanitis G., Rohde C., Yagcioglu E.A., Baptista T., Et al., An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine, Gen Psychiatr, 35, 3, (2022)
  25. Schoretsanitis G., de Leon J., Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s), J Clin Psychiatry, 834, (2022)
  26. van der Zalm Y., Foldager L., Termorshuizen F., Sommer I.E., Nielsen J., Selten J.P., Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study, Acta Psychiatr Scand, 143, 3, pp. 216-226, (2021)
  27. Taipale H., Tanskanen A., Mehtala J., Vattulainen P., Correll C.U., Tiihonen J., 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20), World Psychiatry, 19, 1, pp. 61-68, (2020)
  28. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Et al., 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), Lancet., 374, 9690, pp. 620-627, (2009)
  29. Bachmann C.J., Aagaard L., Bernardo M., Brandt L., Cartabia M., Clavenna A., Et al., International trends in clozapine use: a study in 17 countries, Acta Psychiatr Scand, 136, 1, pp. 37-51, (2017)
  30. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Et al., Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT), Arch Gen Psychiatry, 60, 1, pp. 82-91, (2003)
  31. Citrome L., Volavka J., Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine, Harv Rev Psychiatry, 29, pp. 20-34, (2021)
  32. Hiemke C., Bergemann N., Clement H.W., Conca A., Deckert J., Domschke K., Et al., Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017, Pharmacopsychiatry., 51, 1-2, pp. 9-62, (2018)
  33. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., McNeil J.J., A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls, Aust NZ J Psychiatry, 45, 6, pp. 458-465, (2011)
  34. Schoretsanitis G., Kane J.M., Correll C.U., Marder S.R., Citrome L., Newcomer J.W., Et al., Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie, J Clin Psychiatry, 81, 3, (2020)
  35. Williams R.L., FDA position on product selection for “narrow therapeutic index” drugs, Am J Health-Syst Pharm, 54, 14, pp. 1630-1632, (1997)
  36. Spina E., Hiemke C., de Leon J., Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics, Expert Opin Drug Metab Toxicol, 12, 4, pp. 407-422, (2016)
  37. Moore T.J., Cohen M.R., Furberg C.D., Serious adverse drug events reported to the Food and Drug Administration, 1998-2005, Arch Intern Med, 167, 16, pp. 1752-1759, (2007)
  38. de Leon J., Sanz E.J., De Las C.C., Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions, Schizophr Bull, 46, 1, pp. 1-3, (2020)
  39. de Leon J., Sanz E.J., Noren G.N., De Las C.C., Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics, World Psychiatry, 19, 1, pp. 120-121, (2020)
  40. Rohde C., Siskind D., de Leon J., Nielsen J., Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study, Acta Psychiatr Scand, 142, 2, pp. 78-86, (2020)
  41. Villasante-Tezanos A.G., Rohde C., Nielsen J., de Leon J., Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia, Acta Psychiatr Scand, 142, 1, pp. 66-67, (2020)
  42. Schoretsanitis G., Ruan C.J., Rohde C., Verdoux H., De Las C.C., Spina E., Et al., An update on the complex relationship between clozapine and pneumonia, Expert Rev Clin Pharmacol, 14, 2, pp. 145-149, (2021)
  43. Vohra J., Sudden cardiac death in schizophrenia: a review, Heart Lung Circ, 29, 10, pp. 1427-1432, (2020)
  44. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., Wolfe R., McNeil J.J., Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study, Schizophr Res, 141, 2-3, pp. 173-178, (2012)
  45. Papola D., Ostuzzi G., Gastaldon C., Morgano G.P., Dragioti E., Carvalho A.F., Et al., Antipsychotic use and risk of life- threatening medical events: umbrella review of observational studies, Acta Psychiatr Scand, 140, 3, pp. 227-243, (2019)
  46. Myles N., Myles H., Xia S., Large M., Bird R., Galletly C., Et al., A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia, Aust N Z J Psychiatry, 53, 5, pp. 403-412, (2019)
  47. Wicinski M., Weclewicz M.M., Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring, Curr Opin Hematol, 25, 1, pp. 22-28, (2018)
  48. Shirazi A., Stubbs B., Gomez L., Moore S., Gaughran F., Flanagan R.J., Et al., Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis, Int J Mol Sci, 17, 6, (2016)
  49. West S., Rowbotham D., Xiong G., Kenedi C., Clozapine induced gastrointestinal hypomotility: a potentially life threatening adverse event. A review of the literature, Gen Hosp Psychiaty, 46, pp. 32-37, (2017)
  50. Cohen D., Clozapine and gastrointestinal hypomotility, CNS Drugs, 31, 12, pp. 1083-1091, (2017)
  51. de Leon J., Schoretsanitis G., Kane J.M., Ruan C.J., Using therapeutic drug monitoring to personalize clozapine dosing in Asians, Asia Pac Psychiatry, 12, 2, (2020)
  52. Spina E., de Leon J., Clinically relevant interactions between newer antidepressants and second-generation antipsychotics, Expert Opin Drug Metab Toxicol, 10, 5, pp. 721-746, (2014)
  53. Pacia S.V., Devinsky O., Clozapine-related seizures: experience with 5,629 patients, Neurology., 44, 12, pp. 2247-2249, (1994)
  54. Clancy M.J., Clarke M.C., Connor D.J., Cannon M., Cotter D.R., The prevalence of psychosis in epilepsy
  55. Faber M.S., Fuhr U., Time response of cytochrome P450 1A2 activity on cessation of heavy smoking, Clin Pharmacol Ther, 76, 2, pp. 178-184, (2004)
  56. a systematic review and meta-analysis, BMC Psychiatry, 14, (2014)
  57. Asenjo Lobos C., Komossa K., Rummel-Kluge C., Hunger H., Schmid F., Schwarz S., Et al., Clozapine versus other atypical antipsychotics for schizophrenia, Cochrane Database Syst Rev, 11, (2010)
  58. Trifiro G., Spina E., Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems, Curr Drug Metab, 12, 7, pp. 611-620, (2011)
  59. Nielsen J., Correll C.U., Manu P., Kane J.M., Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?, J Clin Psychiatry, 74, 6, pp. 603-613, (2013)
  60. Sabaawi M., Singh N.N., de Leon J., Guidelines for the use of clozapine in individuals with developmental disabilities, Res Dev Disabil, 27, 3, pp. 309-336, (2006)
  61. Bertilsson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., Et al., Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test, Br J Clin Pharmacol, 38, 5, pp. 471-473, (1994)
  62. Ghotbi R., Christensen M., Roh H.K., Ingelman-Sundberg M., Aklillu E., Bertilsson L., Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans, Eur J Clin Pharmacol, 63, 6, pp. 537-546, (2007)
  63. Perry P.J., Bever K.A., Arndt S., Combs M.D., Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram, Biol Psychiatry, 44, 8, pp. 733-738, (1998)
  64. Haslemo T., Eikeseth P.H., Tanum L., Molden E., Refsum H., The effect of variable cigarette consumption on the interaction with clozapine and olanzapine, Eur J Clin Pharmacol, 62, 12, pp. 1049-1053, (2006)
  65. Dobrinas M., Cornuz J., Oneda B., Kohler Serra M., Puhl M., Eap C.B., Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility, Clin Pharmacol Ther, 90, 1, pp. 117-125, (2011)
  66. Ruan C.J., Wang C.Y., Tang Y.L., Lin S.K., Lee S.T., Hong K.S., Et al., Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13, J Clin Psychopharmacol, 39, 6, pp. 644-648, (2019)
  67. Wagner E., McMahon L., Falkai P., Hasan A., Siskind D., Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis, Acta Psychiatr Scand, 142, 6, pp. 456-466, (2020)
  68. Olesen O.V., Linnet K., Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations, J Clin Pharmacol, 41, 8, pp. 823-832, (2001)
  69. Schoretsanitis G., Kane J.M., Ruan C.J., Spina E., Hiemke C., de Leon J., Comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients, Expert Rev Clin Pharmacol, 12, 7, pp. 603-621, (2019)
  70. Chang W.H., Lin S.K., Lane H.Y., Wei F.C., Hu W.H., Lam Y.W., Et al., Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients, Prog Neuro-Psychopharmacol Biol Psychiatry, 22, 5, pp. 723-739, (1998)
  71. de Leon J., Glucuronidation enzymes, genes and psychiatry, Int J Neuropsychopharmacol, 6, 1, pp. 57-72, (2003)
  72. Loi C.M., Smith D.A., Dalvie D., Which metabolites circulate?, Drug Metab Dispos, 41, 5, pp. 933-951, (2013)
  73. Schaber G., Stevens I., Gaertner H.J., Dietz K., Breyer-Pfaff U., Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance, Br J Clin Pharmacol, 46, 5, pp. 453-459, (1998)
  74. Kuoppamaki M., Syvalahti E., Hietala J., Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists, Eur J Pharmacol, 245, 2, pp. 179-182, (1993)
  75. Ruan C.J., Zang Y.N., Wang C.Y., Cheng Y.H., Sun C., Spina E., Et al., Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review, J Clin Psychopharmacol, 39, 2, pp. 135-144, (2019)
  76. Jerling M., Lindstrom L., Bondesson U., Bertilsson L., Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from therapeutic drug monitoring service, Ther Drug Monit, 169, 4, pp. 368-374, (1994)
  77. de Leon J., Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid, Ther Drug Monit, 42, 1, pp. 159-161, (2020)
  78. Spina E., Barbieri M.A., Cicala G., de Leon., Clinically relevant interactions between atypical antipsychotics and anti-infective agents, Pharmaceuticals (Basel), 13, 12, (2020)
  79. Ruan C.J., Zang Y.N., Cheng Y.H., de Leon J., Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment, Psychother Psychosom, 89, 4, pp. 255-257, (2020)
  80. de Leon J., Atypical antipsychotic dosing: the effect of smoking and caffeine, Psychiatr Serv, 55, 5, pp. 491-493, (2004)
  81. Facciola G., Avenoso A., Scordo M.G., Madia A.G., Ventimiglia A., Perucca E., Et al., Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders, Ther Drug Monit, 21, 3, pp. 341-345, (1999)
  82. Wong J.O., Leung S.P., Mak T., Ng R.M., Chan K.T., Hon-Kee Cheung H., Et al., Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients, Prog Neuro-Psychopharmacol Biol Psychiatry, 30, 2, pp. 251-264, (2006)
  83. Diaz F.J., Santoro V., Spina E., Cogollo M., Rivera T.E., Botts S., Et al., Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables, Pharmacopsychiatry., 41, 3, pp. 81-91, (2008)
  84. Rajkumar A.P., Poonkuzhali B., Kuruvilla A., Jacob M., Jacob K.S., Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia, Int Clin Psychopharmacol, 28, 1, pp. 50-56, (2013)
  85. Spina E., D'Arrigo C., Santoro V., Muscatello M.R., Pandolfo G., Zoccali R., Et al., Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder, Ther Drug Monit, 31, 6, pp. 758-763, (2009)
  86. Diaz F.J., Josiassen R.C., de Leon J., The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial, J Clin Psychopharmacol, 38, 5, pp. 442-446, (2018)
  87. Kuzin M., Haen E., Hiemke C., Bochon B., Bochon K., Grunder G., Paulzen M., Et al., Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis, J Psychopharmacol, 35, 3, pp. 273-278, (2021)
  88. Meltzer H.Y., Clozapine: balancing safety with superior antipsychotic efficacy, Clin Schizophr Relat Psychoses, 6, 3, pp. 134-144, (2012)
  89. Zarezadeh M., Saedisomeolia A., Shekarabi M., Et al., The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies, Eur J Nutr, 60, 6, pp. 2905-2921, (2021)
  90. Moschny N., Hefner G., Grohmann R., Eckermann G., Maier H.B., Seifert J., Et al., Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics, Pharmaceuticals (Basel), 14, 6, (2021)
  91. Clark S.R., Warren N.S., Kim G., Schubert K.O., Kisely S., Forrester T., Et al., Elevated clozapine levels associated with infection: a systematic review, Schizophr Res, 192, pp. 50-56, (2018)
  92. Nielsen R., Akey J.M., Jakobsson M., Pritchard J.K., Tishkoff S., Willerslev E., Tracing the peopling of the world through genomics, Nature., 541, 7637, pp. 302-310, (2017)
  93. de Leon J., Rajkumar A.P., Kaithi A.R., Schoretsanitis G., Kane J.M., Wang C.Y., Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview, Indian J Psychol Med, 42, 1, pp. 4-10, (2020)
  94. Suhas S., Kumar V., Damodharan D., Sharma P., Rao N.P., Varambally S., Et al., Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level?An exploratory study, Schizophr Res, 222, pp. 195-201, (2020)
  95. Gonzalez-Esquivel D.F., Jung-Cook H., Baptista T., de Leon J., Amerindians may need clozapine dosing similar to that of Asians, Rev Psiquiatr Salud Ment, 14, 3, pp. 177-179, (2021)
  96. Menkes D.B., Glue P., Gale C., Lam F., Hung C.T., Hung N., Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients, EBioMedicine., 27, pp. 134-137, (2018)
  97. Zang Y.N., Dong F., Li A.N., Wang C.Y., Guo G.X., Wang Q., Et al., The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients, Eur J Drug Metab Pharmacokinet, 46, 3, pp. 353-371, (2021)
  98. Sathirakul K., Chan C., Teng L., Bergstrom R.F., Yeo K.P., Wise S.D., Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects, Br J Clin Pharmacol, 56, 2, pp. 184-187, (2003)
  99. Marder S.R., Yang Y.S., Chapter 25. Clozapine, The American Psychiatric Association Publishing textbook of psychopharmacology, pp. 623-648, (2017)
  100. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Et al., Sex, race, and smoking impact olanzapine exposure, J Clin Pharmacol, 48, 2, pp. 157-165, (2008)
  101. Ruan C.J., de Leon J., Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?, Pharmacogenomics., 21, 6, pp. 369-373, (2020)
  102. The Dutch Pharmacogenomic Working Group, Phamacogenomic recommendations, farmacogenetica-update, (2020)
  103. Dobrinas M., Cornuz J., Eap C.B., Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers, Pharmacogenet Genomics, 23, 5, pp. 286-292, (2013)
  104. Jakobsen M.I., Larsen J.R., Svensson C.K., Johansen S.S., Linnet K., Nielsen J., Et al., The significance of sampling time in therapeutic drug monitoring of clozapine, Acta Psychiatr Scand, 135, 2, pp. 159-169, (2017)
  105. Schoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppala N., Kopecek M., Et al., European Caucasians may need lower minimum therapeutic clozapine doses than those customarily proposed, J Clin Psychopharmacol, 41, 2, pp. 140-147, (2021)
  106. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., Flanagan R.J., Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients, J Clin Psychopharmacol, 24, 1, pp. 70-78, (2004)
  107. Quiles C., Verdoux H., La clozapine, (2020)
  108. Guideline for the use of clozapine [Internet]
  109. Taylor D.M., Barnes T.R.E., Young A.H., Maudsley prescribing guidelines in psychiatry, (2018)
  110. Meyer J.M., Stahl S.M., The clozapine handbook: Stahl's handbooks (Stahl's essential psychopharmacology handbooks), (2020)
  111. Lieberman J.A., Kane J.M., Johns C.A., Clozapine: guidelines for clinical management, J Clin Psychiatry, 50, 9, pp. 329-338, (1989)
  112. Baldessarini R.J., Frankenburg F.R., Clozapine. A novel antipsychotic agent, N Engl J Med, 324, 11, pp. 746-754, (1991)
  113. Citrome L., Schizophrenia life-threatening and life-saving treatment?, Curr Psychiatr Ther, 8, 12, pp. 57-63, (2009)
  114. de Leon J., Armstrong S.C., Cozza K.L., The dosing of atypical antipsychotics, Psychosomatics., 46, 3, pp. 262-273, (2005)
  115. Simpson G.M., Josiassen R.C., Stanilla J.K., de Leon J., Nair C., Abraham G., Et al., Double-blind study of clozapine dose response in chronic schizophrenia, Am J Psychiatry, 156, 11, pp. 1744-1750, (1999)
  116. Cohen D., Bogers J.P., van Dijk D., Bakker B., Schulte P.F., Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy, J Clin Psychiatry, 73, 10, pp. 1307-1312, (2012)
  117. Siskind D., Sidhu A., Cross J., Chua Y.T., Myles N., Cohen D., Et al., Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy, Aust N Z J Psychiatry, 54, 5, pp. 467-481, (2020)
  118. Wang X.Q., Lv B., Wang H.F., Zhang X., Yu S.Y., Huang X.S., Et al., Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014, J Clin Neurosci, 22, 6, pp. 1005-1011, (2015)
  119. Freudenreich O., Clozapine-induced myocarditis: prescribe safely but do prescribe, Acta Psychiatr Scand, 132, 4, pp. 240-241, (2015)
  120. de Leon J., Tang Y.L., Baptista T., Cohen D., Schulte P.F., Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations, Acta Psychiatr Scand, 132, 4, pp. 242-243, (2015)
  121. Hjorthoj C., Sturup A.E., McGrath J.J., Nordentoft M., Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry, 4, 4, pp. 295-301, (2017)
  122. Bandelow B., Degner D., Kreusch U., Ruther E., Myocarditis under therapy with clozapine, Schizophr Res, 17, 3, pp. 293-294, (1995)
  123. Pui-yin Chung J., Shiu-yin Chong C., Chung K.F., Lai-wah Dunn E., Wai-nang Tang O., Chan W.F., The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong, Can J Psychiatr, 53, 12, pp. 857-862, (2008)
  124. Ifteni P., Nielsen J., Burtea V., Correll C.U., Kane J.M., Manu P., Effectiveness and safety of rapid clozapine titration in schizophrenia, Acta Psychiatr Scand, 130, 1, pp. 25-29, (2014)
  125. Ifteni P., Correll C.U., Nielsen J., Burtea V., Kane J.M., Manu P., Rapid clozapine titration in treatment-refractory bipolar disorder, J Affect Disord, 166, pp. 168-172, (2014)
  126. Aksoy Poyraz C., Turan S., Demirel O.F., Usta Saglam N.G., Yildiz N., Duran A., Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series, Ther Adv Psychopharmacol, 5, 4, pp. 237-242, (2015)
  127. Lochhead J.D., Nelson M.A., Schneider A.L., Risks and benefits of rapid clozapine titration, Ment Illn, 8, 1, (2016)
  128. Chopra N., de Leon J., Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy, Int J Psychiatry Med, 51, 1, pp. 104-115, (2016)
  129. Poyraz C.A., Ozdemir A., Saglam N.G., Turan S., Poyraz B.C., Tomruk N., Et al., Rapid clozapine titration in patients with treatment refractory schizophrenia, Psychiatr Q, 87, 2, pp. 315-322, (2016)
  130. de Leon J., Rhee D.W., Kondracke A., Diuguid-Gerber J., Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York Hospital, Psychosomatics., 61, 1, pp. 102-103, (2020)
  131. Danilewitz M., Rafizadeh R., Bousman C.A., Successful clozapine rechallenge after suspected clozapine-associated myocarditis: a case report, J Clin Psychopharmacol, 41, 2, pp. 218-220, (2021)
  132. Vermeulen J.M., van Rooijen G., van de Kerkhof M.P.J., Sutterland A.L., Correll C.U., de Haan L., Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years, Schizophr Bull, 45, 2, pp. 315-329, (2019)
  133. Verdoux H., Quiles C., de Leon J., Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review, Schizophr Res, 211, pp. 1-9, (2019)

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - ODS/03